Carcinoid Drug Offers Biggest Advance in Over a Decade Says Lexicon CEO

Dr. Anthony on Treatment Benefit With Telotristat Epitrate in Patients With Carcinoid SyndromeПодробнее

Nurses are Vital to the Management of Carcinoid SyndromeПодробнее

LACNETS - "TELESTAR Clinical Trial Results" Dr. LaPuertaПодробнее

New Results In Tests Of Breast Cancer DrugПодробнее

Advances in NET TreatmentПодробнее

Novel Neuroendocrine Tumor (NET) TherapiesПодробнее

FDA Approval for VOD, NDA for Carcinoid Syndrome, European Regulatory Advancements, and MoreПодробнее

Telotristat Etiprate as a Treatment Option for Carcinoid SyndromeПодробнее

Debate: Does everolimus have a role in carcinoid tumors? - YesПодробнее

Carcinoid Clinic - The Nebraska Medical CenterПодробнее

How Carcinoid Syndrome Affects Carcinoid Heart Disease with Jerome S. Zacks, MDПодробнее

Summary of Clinical Trials for Lanreotide to Treat Carcinoid SyndromeПодробнее

Carcinoid Syndrome: A Cancer Coach Live and Carcinoid Cancer Foundation PresentationПодробнее

Dr. Lowell Anthony: Use of Telotristat Etiprate in Patients with Carcinoid SyndromeПодробнее

Neuroendocrine Tumors: Goals of Therapy with Somatostatin AnalogsПодробнее

CARCINOID - USMLE 1Подробнее

Dr. Pommier Discusses Challenges Associated With the Treatment of Carcinoid SyndromeПодробнее

Managing Diarrhea in Patients With Carcinoid SyndromeПодробнее

Why PFS is a Good Outcome Measure for Neuroendocrine TumorsПодробнее